Skip to content

Fundamental and Clinical Pharmacology

ISSN 1472-8206, 0767-3981

7 papers in the library · 115 citations · publishing 1990-2026

Papers

Sort Most recent Most cited

Monitoring of Clinics That Use Direct-to-Consumer Advertising for Off-Label Ketamine in the New York Metropolitan Area: A Cross-Sectional Systematic Web Search.

Fundamental and Clinical Pharmacology July 1, 2026 Nina Abukahok, Steven Lawrence, Samrachana Adhikari et al.

Ketamine is increasingly prescribed in an off-label manner to treat psychiatric disorders, raising concerns about direct-to-consumer advertising and the proliferation of clinics offering ketamine for at-home use without direct medical supervision. We aimed to identify and characterize clinics advertising ketamine for psychiatric conditions online in the New York metropolitan area (New York, New...

DOI: 10.1111/fcp.70095 (opens in new tab) Full text (opens in new tab) Ketamine Direct‐to‐consumer advertising Off‐label prescribing Telehealth

Psilocybin as Transformative Fast‐Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms

Fundamental and Clinical Pharmacology July 16, 2025 Makiath Adebo, Marie Laure Bonnet, Ons Laouej et al. 10 citations

ABSTRACT In the 1950s–60s, serotonergic psychedelic drugs were studied as potential adjuvants to psychotherapy to treat addiction and alcoholism. However, starting in the 70s, preclinical and clinical studies on psychedelics stopped for decades because legislation controlled its recreational use, citing their hallucinogenic and psychotomimetic effects, as well as their abuse potential....

DOI: 10.1111/fcp.70038 (opens in new tab) Psilocybin Antidepressant Transformative learning Pharmacology +1

Safety concerns on the abuse potential of esketamine: Multidimensional analysis of a new anti-depressive drug on the market.

Fundamental and Clinical Pharmacology June 2022 Jules Baudot, Thomas Soeiro, Marine Tambon et al.

Prominent features of esketamine (e.g., similar mechanism of action as ketamine and target population) require to be vigilant regarding its benefits/risks balance and its risks of abuse in real-life settings. The aim of this study was to review all available pharmacological and clinical data to assess the abuse potential of esketamine shortly after its marketing. This multidimensional study is...

Ephenidine, diphenidine, and methoxphenidine complications reported to the French Addictovigilance Network.

Fundamental and Clinical Pharmacology December 1, 2018 Céline Eiden, Sarah Leone-Burgos, Anaïs Serre et al.

Ephenidine, diphenidine, and methoxphenidine belong to the family of diarylethylamines that are psychoactive substances derived from lefetamine (N, N-di-methyl-1,2-diphenylethylamine, also called L-SPA). These dissociative anesthetic compounds act as potent and selective N-methyl-d-aspartate receptor antagonists and were recently classified as narcotic drugs in France. The available data...

DOI: 10.1111/fcp.12395 (opens in new tab) Full text (opens in new tab) Diphenidine Ephenidine Methoxphenidine Recreational use +1

Cannabis smoking impairs driving performance on the simulator and real driving: a randomized, double‐blind, placebo‐controlled, crossover trial

Fundamental and Clinical Pharmacology May 12, 2018 Joëlle Micallef, Julien Dupouey, Élisabeth Jouve et al. 59 citations

Driving experiments in real conditions are considered as a 'gold standard' to evaluate the effects of drugs on driving performance. Several constraints are difficult to manage in these conditions, so driving simulation appears as the best alternative. A preliminary comparison is crucial before being able to use driving simulation as a valid evaluation method. The aim of this study was to design...

Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice.

Fundamental and Clinical Pharmacology 1992 B Francés, R Gout, J Cros et al. 46 citations

In naive mice, ibogaine at a tremorigenic dose (30 mg/kg, ip), did not produce antinociception but did potentiate the antinociceptive potency of morphine in the tail-flick test. In morphine-dependent mice, ibogaine did not eliminate withdrawal symptoms but significantly increased the number of repetitive vertical jumps induced by naloxone, whatever the duration of the chronic morphine...

Reduction of [3H]6-nitroquipazine-labelled 5-hydroxytryptamine uptake sites in rat brain by 3,4-methylenedioxymethamphetamine.

Fundamental and Clinical Pharmacology 1990 Kenji Hashimoto, Tsuyoshi Goromaru

3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy) is a known neurotoxin to 5-hydroxytryptamine (5-HT; serotonin) nerve terminals. It has recently been demonstrated that [3H]6-nitroquipazine is a new radioligand for studying the 5-HT transport system in brain. Therefore, we examined the effects of repeated systemic administration (10 mg/kg ip, twice daily for 3 d) of MDMA on...